VTT Technical Research Center of Finland received an innovation prize for the technological development work behind an allergy vaccine.
The award ceremony was held in Brussels in December 2013. VTT’s patents are based on application of gene technology to alter the structure of an allergen – a protein causing allergy – so that it will cause fewer allergic symptoms while remaining effective in desensitisation therapy.
VTT spin-off Desentum is responsible for developing and commercializing new generation immunotherapeutic products based on the VTT technology.